

PRESS RELEASE

ASN Contacts: Christine Feheley (202) 640-4638 | <u>cfeheley@asn-online.org</u> Tracy Hampton <u>thampton@nasw.org</u>

DO ACCOUNTABLE CARE ORGANIZATIONS REDUCE KIDNEY FAILURE-RELATED HEALTHCARE COSTS?

Highlights

- A recent analysis indicates that Accountable Care Organizations may reduce the cost of medical care for patients undergoing dialysis.
- The cost savings were seen only for patients who regularly received care from primary care physicians.

Washington, DC (November 24, 2020) — Accountable Care Organizations (ACOs) were linked to modest cost savings for the care of Medicare beneficiaries undergoing long-term dialysis. The findings come from an analysis that will appear in an upcoming issue of *CJASN*.

An ACO is a group of clinicians and hospitals who come together voluntarily to give coordinated high-quality care to a designated group of patients, with the goal of improving care while reducing its cost. To examine whether ACOs save money for the care of patients with kidney failure undergoing dialysis—a group whose care is especially expensive—a team led by Vahakn B. Shahinian, MD, MS and Shivani Bakre, BBA (University of Michigan) analyzed national Medicare claims data from a 20% random sample of beneficiaries receiving dialysis before 2017.

The researchers found that the percent of long-term dialysis beneficiaries assigned to an ACO increased from 6% to 23% from 2012 to 2016. Spending on these beneficiaries was \$143 less per quarter (or \$572 per year) than spending for beneficiaries not assigned to an ACO. More detailed analyses revealed that savings occurred only for beneficiaries in ACOs who regularly received care from primary care physicians.

"There are newer programs directed specifically at this group of patients, including the End-Stage Renal Disease Seamless Care Organization, or ESCO, program started in October 2015 and the upcoming Advancing American Kidney Health Initiative," said Dr. Shahinian. "Our study looked at an older and more general program, the Medicare Shared Savings Program ACOs, which started in 2012 and were directed to the Medicare population in general. In future work, it will be of interest to see if the newer, more kidney disease–specific programs will do even better than the ACO programs were able to achieve."

An accompanying editorial re-iterates this thought, noting that "one reason why savings among ACO beneficiaries receiving long-term dialysis are small—or nonexistent—may be because many ACOs do not focus specifically on patients with end-stage kidney disease."

Study co-authors include John Hollingsworth, MD, MS; Phyllis Yan, MS; Emily Lawton, MPP; and Richard Hirth, PhD.

Disclosures: The authors reported no financial disclosures.

The article, titled "Accountable Care Organizations and Spending for Patients Undergoing Long-Term Dialysis," will appear online at http://cjasn.asnjournals.org/ on November 24, 2020, doi: 10.2215/CJN.02150220.

The editorial, titled, "ACOs and Bending the Cost Curve for Health Care Spending for People with Kidney Failure," will appear online at http://cjasn.asnjournals.org/ on November 24, 2020, doi: 10.2215/CJN.16521020.

The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 21,000 members representing 131 countries. For more information, visit <u>www.asn-online.org</u>.

###